Chiome Bioscience Inc. (JP:4583)
:4583
Want to see JP:4583 full AI Analyst Report?
4583 Stock Chart & Stats
¥106.00
-¥13.00(-4.94%)
At close: 4:00 PM EST
¥106.00
-¥13.00(-4.94%)
Day’s Range― - ―
52-Week Range¥69.00 - ¥168.00
Previous CloseN/A
Volume5.12M
Average Volume (3M)521.30K
Market Cap
¥5.28B
Enterprise Value¥4.90B
Total Cash (Recent Filing)¥1.47B
Total Debt (Recent Filing)¥260.50M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.69
Shares Outstanding76,543,100
10 Day Avg. Volume796,530
30 Day Avg. Volume521,303
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)6.47
Price to Sales (P/S)12.25
P/FCF Ratio-7.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary ADC/antibody PlatformChiome's proprietary antibody and ADC discovery platform creates a durable competitive asset: platforms can generate multiple candidates, attract partnerships and non-dilutive funding, and create long-term licensing or royalty revenue streams if clinical success occurs.
Low Leverage / Modest DebtRelatively low debt levels reduce near-term solvency risk and interest burden while the company pursues costly clinical development. Modest leverage gives strategic flexibility to raise capital, partner programs, or absorb R&D volatility over the coming months.
Consistently Solid Gross MarginsSustained gross margins near the mid-50s indicate favorable unit economics at the product-revenue level. If Chiome can commercialize candidates or secure higher-margin licensing deals, these margins support path to profitability once fixed R&D costs are covered and scale is achieved.
Bears Say
Persistent Negative Cash FlowOperating and free cash flows have been materially negative and track accounting losses, creating a sustained cash burn. Over a multi-month horizon this increases funding risk, may force dilutive financings or accelerated partnerships, and constrains independent program funding.
Deep, Volatile Operating LossesVery large negative margins and uneven revenue trends (2025 revenue down ~23%) show the company remains far from profitable scale. Persistent heavy losses erode equity and require either significant top-line progress or continual external funding to sustain operations.
Small Organizational ScaleA 47-person workforce limits simultaneous clinical and commercial initiatives, increasing execution risk and reliance on partners. Scaling development, regulatory and commercialization efforts will require significant hiring and capital, challenging while burn remains high.
Chiome Bioscience Inc. News
4583 FAQ
What was Chiome Bioscience Inc.’s price range in the past 12 months?
Chiome Bioscience Inc. lowest stock price was ¥69.00 and its highest was ¥168.00 in the past 12 months.
What is Chiome Bioscience Inc.’s market cap?
Chiome Bioscience Inc.’s market cap is ¥5.28B.
When is Chiome Bioscience Inc.’s upcoming earnings report date?
Chiome Bioscience Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 62 days.
How were Chiome Bioscience Inc.’s earnings last quarter?
Chiome Bioscience Inc. released its earnings results on May 14, 2026. The company reported -¥3.31 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.31.
Is Chiome Bioscience Inc. overvalued?
According to Wall Street analysts Chiome Bioscience Inc.’s price is currently Overvalued.
Does Chiome Bioscience Inc. pay dividends?
Chiome Bioscience Inc. does not currently pay dividends.
What is Chiome Bioscience Inc.’s EPS estimate?
Chiome Bioscience Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chiome Bioscience Inc. have?
Chiome Bioscience Inc. has 76,543,100 shares outstanding.
What happened to Chiome Bioscience Inc.’s price movement after its last earnings report?
Chiome Bioscience Inc. reported an EPS of -¥3.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.064%.
Which hedge fund is a major shareholder of Chiome Bioscience Inc.?
Currently, no hedge funds are holding shares in JP:4583
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chiome Bioscience Inc.
Chiome Bioscience Inc. is a global company dedicated to the research and development of cutting-edge technology platforms for drug discovery. Its operations are structured into two primary divisions: the Drug Discovery Business and the Drug Discovery Support Business. The company offers key proprietary technologies, including the ADLib System, a platform for generating monoclonal antibodies essential for drug discovery and development, and the Human ADLib System, which engineers chicken antibody genes into humanized therapeutic antibodies. Additionally, Chiome Bioscience provides a range of support services, such as protein expression and purification, stable cell line generation for recombinant protein and antibody production, and bespoke antibody generation utilizing either its ADLib system or B cell cloning techniques. Chiome Bioscience boasts a robust product pipeline with several candidates currently in Phase 1 clinical trials. These include: ADCT-701: an anti-dlk1 antibody targeting liver cancer. CBA-1205: an afucosylated anti-dlk1 antibody indicated for liver cancer, lung cancer, and neuroblastoma. CBA-1535: an anti-5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). Furthermore, its preclinical pipeline features: LIV-2008/2008b: an anti-TROP-2 antibody aimed at treating TNBC, lung cancer, and colorectal cancer. BMAA: an anti-semaphorin3a antibody for central nervous system, immune/inflammatory, neurological, and ophthalmic diseases. PCDC: an anti-CDCP1 antibody targeting lung, colorectal, pancreatic, breast, and ovarian tumors. PTRY: a multi-specific 5T4/CD3/PD-L1 antibody designed for malignant mesothelioma, SCLC, NSCLC, and triple-negative breast cancer. PFKR: an anti-CX3CR1 antibody focused on secondary progressive multiple sclerosis. The company's services and technologies benefit a diverse clientele, including universities, research institutions, and pharmaceutical companies. Established in 2005, Chiome Bioscience Inc. maintains its headquarters in Tokyo, Japan.
Technical Analysis
Peptidream
―
Sosei Group
―
Immuno-Biological Laboratories Co., Ltd.
―
RaQualia Pharma Inc.
―
Oncolys BioPharma, Inc.
―